Technology
Health
Pharmaceutical

Nightstar Therapeutics

$25.29
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.02 (-0.08%) Today
$0.00 (0.00%) After Hours

Why Robinhood?

You can buy or sell NITE and other stocks, options, ETFs, and crypto commission-free!

About

Nightstar Therapeutics plc American Depositary Shares, also called Nightstar Therapeutics, is a clinical-stage gene therapy holding company, which engages in the development and commercialization of novel one-time treatments for patients suffering from rare inherited retinal diseases. Its pipeline includes NSR-REP1, for the treatment of choroideremia; NSR-RPGR, for the treatment of X-linked retinitis pigmentosa; and NSR-BEST1, for the treatment of vitelliform macular dystrophy. Read More The company was founded by Robert MacLaren on July 6, 2017 and is headquartered in London, the United Kingdom.

Employees
27
Headquarters
London, Greater London
Founded
2017
Market Cap
730.88M
Price-Earnings Ratio
Dividend Yield
0.00
Average Volume
176.30K
High Today
$25.44
Low Today
$25.25
Open Price
$25.25
Volume
246.70K
52 Week High
$29.55
52 Week Low
$9.59

Collections

Technology
Health
Pharmaceutical
Therapy
Medical
2017 IPO
UK
Europe

News

Seeking AlphaMar 12

Biogen Is Next In Line With Purchase Of Gene Therapy Biotech

There has been a massive increase this year for either acquisitions or partnerships being formed with gene therapy companies, with the likelihood that more deals are likely on the way.

90
MarketBeatMar 9

Stock Price, News, & Analysis for Nightstar Therapeutics

Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom.

4
MarketWatchMar 5

Nightstar Therapeutics PLC ADR

Shares of Nightstar Therapeutics PLC rocketed 67% to pace all premarket gainers in very active trade, after the gene therapy company agreed to be acquired by Biogen Inc.

147

Earnings

-$0.52
-$0.40
-$0.27
-$0.15
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
Actual
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.